Full-Time
Hospital Senior Account Manager
Anti-Infectives
GSK
10,001+ employees
Develops medicines, vaccines, and consumer health
Compensation Overview
$165k - $275k/yr
Virginia Beach, VA, USA + 2 more
More locations: Richmond, VA, USA | Roanoke, VA, USA
Hybrid
Field-based territory role requiring travel up to 50%, including overnight travel.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to GSK
See people who can refer or advise you
- A BA/BS degree from an accredited institution is required.
- A valid driver's license is required.
- At least 5 years of experience in the pharmaceutical, medical, or biotechnology industry is required.
- At least 3 years of experience calling on hospitals and health systems is required.
- Experience with hospital decision-making processes, clinical pathways, formulary management, and antimicrobial stewardship programs is required.
- Willingness to travel up to 50% within the assigned geography, including overnight travel, is required.
- Ability to lift and/or move up to 35 pounds is required.
- Support and advance formulary access, protocol and order set readiness, discharge pathway support, and demand generation across targeted hospital accounts.
- Engage infectious disease physicians, hospitalists, pharmacists, case management teams, discharge planners, and health-system decision makers to drive sales.
- Develop, implement, and execute an integrated territory business plan covering key customer targets within assigned accounts.
- Manage hospital relationships by engaging clinical and non-clinical stakeholders to understand customer needs and priorities.
- Provide scientific and clinical information within the disease-state area and for approved products.
- Deliver sales presentations of approved products to physicians, advanced practice providers, medical staff, and other appropriate clinical personnel.
- Use and manage available resources to optimize customer engagement.
- Collaborate with Organized Provider Account Directors, Reimbursement Managers, and other cross-functional stakeholders to drive aligned execution and business success.
- Achieve and exceed sales targets by prioritizing high-value customers and growth opportunities.
- Secure and translate hospital formulary wins and market-access achievements into consistent prescribing and utilization within targeted hospital accounts.
- Engage pharmacy, medical, and operational stakeholders in clinical discussions supporting patient identification, treatment selection, intravenous-to-oral transition, discharge readiness, and readmission reduction.
- Facilitate collaboration with nurse navigators, discharge planners, case managers, and specialty pharmacy partners to support patient access and therapy continuity.
- Identify and address clinical, operational, behavioral, and process-related barriers affecting product adoption.
- Plan and organize activities to achieve call metrics and optimize coverage and frequency for key customers.
- Deliver comprehensive clinical brand presentations to physicians and other healthcare professionals to drive appropriate product utilization.
- Understand the healthcare delivery system within each assigned account, including physician hierarchy, pharmacy personnel, and clinical nursing staff.
- Develop in-depth product and account knowledge and stay informed about local and regional market trends.
- Analyze utilization trends, customer insights, and local market dynamics to identify opportunities and drive performance.
- Conduct educational programs, in-services, speaker programs, and compliant scientific discussions.
- Collaborate with peers in the sales organization to share best practices and strategies.
- Provide feedback on marketing strategy, analyze sales-activity and territory-performance effectiveness, and develop territory plans with the Regional Sales Director, brand team, and support partners.
- Manage the territory budget to support sales and marketing activities.
- Complete administrative tasks promptly and execute company brand strategy and tactics within the assigned geographic area.
- Participate in training and development programs.
- Maintain compliance with corporate and industry policies and procedures.
- A consistent record of top-tier sales performance and proven product-launch success is preferred.
- Demonstrated success driving demand generation within hospitals is preferred.
- Anti-infective experience is preferred.
- Expertise in account selling and managing complex sales processes is preferred.
- Deep knowledge of the health-systems business model, organizational structure, stakeholder roles, and decision-making processes, including P&T committees and formularies, is preferred.
- Experience engaging specialist physicians, hospitalists, pharmacists, and pharmacy leadership is preferred.
- Experience collaborating across hospital and community-care settings is preferred.
- Ability to analyze data and trends to create actionable business plans is preferred.
- Demonstrated ability to adhere to regulatory, legal, and compliance standards is preferred.
- Exceptional presentation and selling skills, together with strong business acumen, are preferred.
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
Get referred to GSK
See people who can refer or advise you
Simplify's Take
What believers are saying
- Hutchmed licensed HMPL-A830 to GSK on September 3, 2026, adding KRAS-EGFR oncology optionality.
- GSK expects more than 20 late-stage study starts in 2026, accelerating pipeline turnover.
- Japan approved Hibsago for chronic hepatitis B on August 24, 2026, expanding specialty revenues.
What critics are saying
- Dolutegravir HIV exclusivity rolls off between 2028 and 2030, threatening major revenue.
- Trelegy Ellipta faces Teva generic litigation, with Florida trial set for February 22, 2028.
- £2.4 billion restructuring costs and undisclosed job cuts risk execution slippage across 2026-2027.
What makes GSK unique
- GSK’s 2026 pipeline spans oncology, vaccines, and HIV, diversifying single-asset dependence.
- Blenrep won Singapore HSA approval on August 19, 2026, validating the anti-BCMA platform.
- GSK’s mRNA flu vaccine entered Phase III in September 2026 after strong Phase II data.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Company News
HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy. 3 September 2026 HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPL-A830, an investigational antibody-targeted therapy conjugate (ATTC) designed to target KRAS and EGFR in solid tumours. EGFR is an established driver of tumour growth in several solid cancers, including colorectal, pancreatic and non-small-cell lung cancers. It also plays an important role in resistance to KRAS-targeted treatments, particularly in colorectal cancer. Targeting both EGFR and KRAS is therefore intended to provide broader and more durable pathway inhibition. Under the agreement, GSK will receive worldwide development and commercialisation rights for HMPL-A830 outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED will receive an upfront payment of US$110 million, along with potential development, regulatory and commercial milestone payments of up to US$1.295 billion and royalties on net sales. HMPL-A830 combines a selective KRAS small-molecule inhibitor with an antibody that targets the epidermal growth factor receptor (EGFR). The approach is designed to deliver the KRAS inhibitor directly to EGFR-expressing tumour cells while also blocking EGFR and KRAS signalling. The initial clinical development programme will focus on colorectal, pancreatic and lung cancers, which have high rates of KRAS alterations. KRAS mutations are particularly common in colorectal cancer, lung adenocarcinoma and pancreatic ductal adenocarcinoma. Despite recent advances in KRAS-targeted treatments, many patients, particularly those with KRAS mutations other than G12C, continue to have limited treatment options. Resistance to existing therapies and toxicities associated with broader KRAS and RAS inhibition also remain challenges. HUTCHMED will lead the global Phase I development programme for HMPL-A830, which is expected to begin in the second half of 2026. GSK will take responsibility for subsequent clinical development and commercialisation activities outside Mainland China, Hong Kong, Macau and Taiwan. The agreement marks HUTCHMED's first licensing deal with a global partner for an asset from its ATTC platform and expands GSK's oncology pipeline with a novel dual-targeting approach.
GSK shares fall: mRNA flu vaccine advances to next study phase. September 1, 2026, 11:12 a.m. GSK is making progress with the development of an mRNA-based flu vaccine. As the British pharmaceutical company announced, a late-stage study for the vaccine candidate will begin in September. In a mid-stage study with younger and older adults, the drug showed stronger immune responses compared with standard and high-dose flu vaccines, according to GSK. The vaccine was generally well tolerated. "Given one billion flu cases and up to 650,000 deaths worldwide each year, there is a need for next-generation vaccine approaches," said Sanjay Gurunathan, head of research and development for vaccines and infectious diseases at GSK. Messenger RNA is the technology that Moderna as well as Pfizer and BioNTech used to develop their Covid-19 vaccines. In trading on the London Stock Exchange, GSK shares were temporarily down 0.51 percent at 18.44 GBP. DJG/DJN/mgo/hab By Adria Calatayud Selected leveraged products on GSK. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on GSK. The base prospectus as well as the final terms and the basic information sheets can be obtained here: MM5AMJ, MM2M8P, MM18AM, MM2LN9, MM0WV7. Please also note the further information** regarding this advertisement. Risk warning: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.
GSK advances mRNA flu shot after Phase II success. 1,871.00p. 14:02 01/09/26. Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III after reporting positive Phase II results at the OPTIONS XIII influenza conference. 10,770.55. 5,869.38. 5,805.44. 23,612.26. 14:01 01/09/26. GSK said the candidate generated higher immune responses across all tested strains than both standard-dose and high-dose inactivated flu vaccines in younger and older adults, and was generally well tolerated. The Phase III study, due to begin in September, will be the first late-stage trial of an mRNA flu vaccine designed to target both haemagglutinin (HA) and neuraminidase (NA) - the two key surface antigens that help the virus bind and spread. Licensed flu vaccines primarily target HA, but GSK said growing evidence suggests adding NA could improve protection, reduce illness severity and help curb transmission. Sanjay Gurunathan, GSK's head of vaccines and infectious diseases R&D, said: "These promising data support the potential to better protect people from flu with a vaccine designed to target both HA and NA. With one billion flu cases worldwide each year and up to 650,000 deaths there is a need for next generation vaccine approaches. This result is a significant advance in our cutting-edge mRNA programme, and we look forward to starting phase III imminently." As of 1100 BST, GSK shares were down 0.27% at 1,848.50p. Reporting by Iain Gilbert at Sharecast.com
GSK's mRNA flu vaccine Phase 3 trial tests two targets. Healthcare Commercial Intelligence September 01, 2026 Highlights. * GSK is preparing to begin a Phase 3 clinical trial of its experimental messenger RNA vaccine for seasonal influenza. * Phase 2 results showed higher immune responses against all influenza strains compared with currently available vaccines. * The vaccine candidate is designed to target both hemagglutinin and neuraminidase, and GSK has selected the optimized B-strain HA candidate for Phase 3 testing. With respiratory virus season approaching, GSK is preparing to begin a Phase 3 clinical trial evaluating its experimental messenger RNA vaccine for seasonal influenza. The company disclosed the plan after reporting Phase 2 results that showed higher immune responses against all influenza strains compared with currently available vaccines. Those results in younger and older adults were presented Tuesday at the OPTIONS XIII Conference for the Control of Influenza in Washington, D.C. GSK said currently available flu vaccines spark an immune response to hemagglutinin, or HA, a protein on the surface of the pathogen that helps it bind to a cell. The company said growing evidence suggests targeting both HA and neuraminidase, or NA, could improve protection, illness severity, and virus transmission. GSK's seasonal vaccine is a multivalent candidate that addresses both proteins. The company also said previous studies highlighted the need to improve the ability to prompt an immune response to HA protein from the influenza B strain. The Phase 2 test in 971 adults assessed two similar mRNA vaccines. FLUm3HA.b-3NA was designed to encode an optimized B-strain HA, while FLUm3HA-3NA encodes non-optimized B/HA. GSK said both vaccines demonstrated robust immune responses to HA and NA from influenza A and B strains in younger and older adults. The company described the side effect profile and safety as acceptable and selected the optimized B-strain HA vaccine candidate for Phase 3 testing, which is expected to begin later this month. Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases Research and Development, said in a prepared statement that the data support the potential to better protect people from flu with a vaccine designed to target both HA and NA. GSK also said the first mRNA vaccine for seasonal flu is moving toward the market after the FDA's August approval of Moderna's mFLUSIVA, which addresses only the HA protein. GSK acquired its mRNA vaccine candidates from CureVac in 2024 for €400 million, or about $431.4 million, up front. company spotlight Osirium. In the current world of outsourcing, it can be hard to see who has privileged access to what on your systems. These days, the lowest paid people have the highest privileges - and they may not even work for your organisation. Osirium readdresses this balance for end-user organisations and uniquely allows MSSPs to manage tens of thousands of account credentials, outsource safely and keep their clients happy on the compliance front. more top stories September 02, 2026 * Teva said its experimental drug prevented intestinal damage in patients with celiac disease in a mid-stage clinical trial. * The Phase 2a study also showed lower gastrointestinal symptom scores and found the drug was safe and well tolerated. * Teva plans a multiple-dose Phase 2 study to define the dose and regimen for a Phase 3 test. An experimental Teva Pharmaceutical Industries drug prevented intestinal damage in patients with celiac disease, meeting the main goal of a mid-stage clinical trial in the autoimmune disease of the gut that has no FDA-approved therapies. The preliminary Phase 2a results reported Wednesday for TEV-53408, also called TEV 408, showed lower gastrointestinal symptom scores compared with a placebo. Teva said the study drug has been safe and well tolerated so far, and that more data will be presented at a future scientific meeting. The placebo-controlled study enrolled 50 adults with celiac disease who were on a gluten-free diet and had minimal intestinal damage at baseline. Two weeks after a single dose of the study drug, patients began a six-week daily gluten challenge. Researchers assessed the state of the intestines with biopsy measures and patient-reported symptoms. At the end of week 8, Teva said the results showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage compared with a placebo. TEV-53408 is a monoclonal antibody designed to block interleukin-15, a signaling protein involved in immune-mediated pathways, including inflammation and intestinal damage linked to celiac disease. Teva said patients in the study will continue to be followed through week 80 to assess durability and safety. The company also said it will proceed to a multiple-dose Phase 2 study to define the dose and regimen for a Phase 3 test, supported by an agreement with Royalty Pharma earlier this year. September 02, 2026 * Thyme Care secured more than $125 million in Series E financing and said its valuation is now over $2 billion. * The company announced a new parent entity, Thyme Companies, to build a portfolio of independent oncology businesses. * The funding will support Thyme Care's value-based care business and the growth of Thyme Companies. Thyme Care announced Wednesday that it secured more than $125 million in Series E financing, lifting its valuation to over $2 billion. The oncology company also said it has created a new parent company aimed at building a portfolio of businesses that address different parts of the oncology space. Based in Nashville, Tennessee, Thyme Care was founded in 2020 and works with health plans, employers and risk-bearing providers to support patients with cancer. The company provides care navigation services, technology and data insights, and therapeutic interventions. It helps patients understand their diagnosis, find a cancer doctor and receive clinical care between appointments. Patients also have access to a team of providers, nurses and resource specialists. The company said its services are available to 10.5 million people across all 50 states. The Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. Thyme Care said Thyme Companies will build a portfolio of independent oncology businesses focused on accelerating adoption of lower-cost biosimilars and increasing clinical trial enrollment. The first business is expected to launch later this year. Robin Shah will become executive chairman of Thyme Companies, while Thyme Care will continue under CEO Dr. Brad Diephuis, with Co-Founder Dr. Bobby Green serving as president and chief medical officer. Diephuis said the funding will drive Thyme Care's value-based care business while supporting the growth of Thyme Companies. He also said the company's core business is profitable and growing, and that the capital will allow it to scale and expand further into the commercial market and more parts of the oncology care process.
GSK Capital B.V., the Dutch financing arm of pharmaceutical company GSK plc, has priced a €3.5 billion four-tranche bond offering. The issuance includes an €850 million floating-rate note due 2028, priced at three-month Euribor plus 30 basis points. The offering also comprises a €1 billion four-year fixed-rate tranche due 2030 with a 3.50% coupon, €850 million of eight-year notes due 2034 carrying a 3.875% coupon, and €800 million of 11-year notes due 2037 with a 4.125% coupon. Settlement is scheduled for 7 September 2026. BNP Paribas and BofA Securities acted as global coordinators, whilst BNP Paribas, BofA Securities, HSBC, Santander and Standard Chartered Bank served as active bookrunners.